Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 152

1.

A comparison of continuous intravenous insulin and subcutaneous insulin among patients with type 2 diabetes and congestive heart failure exacerbation.

Dungan KM, Osei K, Gaillard T, Moore J, Binkley P.

Diabetes Metab Res Rev. 2014 Jun 10. doi: 10.1002/dmrr.2569. [Epub ahead of print]

PMID:
24916838
[PubMed - as supplied by publisher]
2.

The effect of caffeine on tear secretion.

Osei KA, Ovenseri-Ogbomo G, Kyei S, Ntodie M.

Optom Vis Sci. 2014 Feb;91(2):171-7. doi: 10.1097/OPX.0000000000000129.

PMID:
24240351
[PubMed - indexed for MEDLINE]
3.

Regional and overall aortic function in nondiabetic individuals with insulin resistance and normal glucose tolerance.

Stakos DA, Boudoulas KD, Gaillard TR, Schuster DP, Osei K, Boudoulas H.

J Clin Endocrinol Metab. 2013 Nov;98(11):4457-63. doi: 10.1210/jc.2013-2276. Epub 2013 Sep 24.

PMID:
24064690
[PubMed - indexed for MEDLINE]
4.

Prandial insulin dosing using the carbohydrate counting technique in hospitalized patients with type 2 diabetes.

Dungan KM, Sagrilla C, Abdel-Rasoul M, Osei K.

Diabetes Care. 2013 Nov;36(11):3476-82. doi: 10.2337/dc13-0121. Epub 2013 Sep 23.

PMID:
24062326
[PubMed - in process]
5.

Exercise-mediated changes in high-density lipoprotein: impact on form and function.

Blazek A, Rutsky J, Osei K, Maiseyeu A, Rajagopalan S.

Am Heart J. 2013 Sep;166(3):392-400. doi: 10.1016/j.ahj.2013.05.021. Epub 2013 Jul 3. Review.

PMID:
24016485
[PubMed - indexed for MEDLINE]
6.

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators.

N Engl J Med. 2013 Oct 3;369(14):1317-26. doi: 10.1056/NEJMoa1307684. Epub 2013 Sep 2.

PMID:
23992601
[PubMed - indexed for MEDLINE]
Free Article
7.

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial.

Bode BW, Buse JB, Fisher M, Garg SK, Marre M, Merker L, Renard E, Russell-Jones DL, Hansen CT, Rana A, Heller SR; BEGIN® Basal-Bolus Type 1 trial investigators.

Diabet Med. 2013 Nov;30(11):1293-7. doi: 10.1111/dme.12243. Epub 2013 Jun 17.

PMID:
23710902
[PubMed - indexed for MEDLINE]
Free Article
8.

Determinants of weight gain in the action to control cardiovascular risk in diabetes trial.

Fonseca V, McDuffie R, Calles J, Cohen RM, Feeney P, Feinglos M, Gerstein HC, Ismail-Beigi F, Morgan TM, Pop-Busui R, Riddle MC; ACCORD Study Group.

Diabetes Care. 2013 Aug;36(8):2162-8. doi: 10.2337/dc12-1391. Epub 2013 Feb 14.

PMID:
23412077
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Effect of the approach to insulin therapy on glycaemic fluctuations and autonomic tone in hospitalized patients with diabetes.

Dungan KM, Osei K, Sagrilla C, Binkley P.

Diabetes Obes Metab. 2013 Jun;15(6):558-63. doi: 10.1111/dom.12069. Epub 2013 Feb 17.

PMID:
23350696
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Exenatide pretreatment improved graft function in nonhuman primate islet recipients compared to treatment after transplant only.

Buss JL, Rajab A, Essig ED, Bergdall VK, Wang J, Osei K.

J Transplant. 2012;2012:382518. doi: 10.1155/2012/382518. Epub 2012 Sep 27.

PMID:
23056916
[PubMed]
Free PMC Article
11.

Characterization of metabolically unhealthy overweight/obese African American women: significance of insulin-sensitive and insulin-resistant phenotypes.

Gaillard TR, Schuster D, Osei K.

J Natl Med Assoc. 2012 Mar-Apr;104(3-4):164-71.

PMID:
22774383
[PubMed - indexed for MEDLINE]
12.

Basal insulin and cardiovascular and other outcomes in dysglycemia.

ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):319-28. doi: 10.1056/NEJMoa1203858. Epub 2012 Jun 11.

PMID:
22686416
[PubMed - indexed for MEDLINE]
Free Article
13.

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. Epub 2012 Jun 11.

PMID:
22686415
[PubMed - indexed for MEDLINE]
Free Article
14.

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M, Rosenstock J, Endahl LA, Francisco AM, Hollander P; NN1250-3582 (BEGIN BB T2D) Trial Investigators.

Lancet. 2012 Apr 21;379(9825):1498-507. doi: 10.1016/S0140-6736(12)60205-0.

PMID:
22521072
[PubMed - indexed for MEDLINE]
15.

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, Renard E, Russell-Jones D, Philotheou A, Francisco AM, Pei H, Bode B; BEGIN Basal-Bolus Type 1 Trial Investigators.

Lancet. 2012 Apr 21;379(9825):1489-97. doi: 10.1016/S0140-6736(12)60204-9.

PMID:
22521071
[PubMed - indexed for MEDLINE]
16.

Proinsulin atypical maturation and disposal induces extensive defects in mouse Ins2+/Akita β-cells.

Yuan Q, Tang W, Zhang X, Hinson JA, Liu C, Osei K, Wang J.

PLoS One. 2012;7(4):e35098. doi: 10.1371/journal.pone.0035098. Epub 2012 Apr 3.

PMID:
22509386
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

β-Cells with relative low HIMP1 overexpression levels in a transgenic mouse line enhance basal insulin production and hypoxia/hypoglycemia tolerance.

Zhang X, Degenstein L, Cao Y, Stein J, Osei K, Wang J.

PLoS One. 2012;7(3):e34126. doi: 10.1371/journal.pone.0034126. Epub 2012 Mar 21.

PMID:
22470529
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Correction of aberrant NADPH oxidase activity in blood-derived mononuclear cells from type II diabetes mellitus patients by a naturally fermented papaya preparation.

Dickerson R, Deshpande B, Gnyawali U, Lynch D, Gordillo GM, Schuster D, Osei K, Roy S.

Antioxid Redox Signal. 2012 Aug 1;17(3):485-91. doi: 10.1089/ars.2011.4292. Epub 2012 Apr 26.

PMID:
22369197
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Health-related quality of life and treatment satisfaction in the Sensor-Augmented Pump Therapy for A1C Reduction 3 (STAR 3) trial.

Rubin RR, Peyrot M; STAR 3 Study Group.

Diabetes Technol Ther. 2012 Feb;14(2):143-51. doi: 10.1089/dia.2011.0162. Epub 2011 Dec 1.

PMID:
22133037
[PubMed - indexed for MEDLINE]
20.

Substrate-favored lysosomal and proteasomal pathways participate in the normal balance control of insulin precursor maturation and disposal in β-cells.

Zhang X, Yuan Q, Tang W, Gu J, Osei K, Wang J.

PLoS One. 2011;6(11):e27647. doi: 10.1371/journal.pone.0027647. Epub 2011 Nov 10.

PMID:
22102916
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk